278 related articles for article (PubMed ID: 2295791)
1. C3, C4, and the terminal complement complex differ from C1q by binding predominantly to the antigenic part of solid phase immune complexes.
Garred P; Michaelsen TE; Aase A; Mollnes TE
J Immunol; 1990 Jan; 144(1):198-203. PubMed ID: 2295791
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
[TBL] [Abstract][Full Text] [Related]
3. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
Baatrup G; Jonsson H; Sjöholm A; Sturfelt G; Svehag SE
J Clin Lab Immunol; 1988 Jun; 26(2):73-9. PubMed ID: 3264027
[TBL] [Abstract][Full Text] [Related]
4. Complement activation by immunoglobulin does not depend solely on C1q binding.
Bindon CI; Hale G; Waldmann H
Eur J Immunol; 1990 Feb; 20(2):277-81. PubMed ID: 2311645
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of immune precipitation by complement.
Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.
Kievits F; Kijlstra A
Immunology; 1985 Mar; 54(3):449-56. PubMed ID: 3844370
[TBL] [Abstract][Full Text] [Related]
7. Anti-C1q column: ligand specific purification of immune complexes from human serum or plasma. Analysis of the interaction between C1q and immune complexes.
Kilgallon W; Amlot PL; Williams BD
Clin Exp Immunol; 1982 Jun; 48(3):705-14. PubMed ID: 6811171
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil Fc gamma and complement receptors involved in binding soluble IgG immune complexes and in specific granule release induced by soluble IgG immune complexes.
Voice JK; Lachmann PJ
Eur J Immunol; 1997 Oct; 27(10):2514-23. PubMed ID: 9368604
[TBL] [Abstract][Full Text] [Related]
9. Relative inefficiency of terminal complement activation.
Bhakdi S; Fassbender W; Hugo F; Carreno MP; Berstecher C; Malasit P; Kazatchkine MD
J Immunol; 1988 Nov; 141(9):3117-22. PubMed ID: 3262681
[TBL] [Abstract][Full Text] [Related]
10. A study of in vivo immune complex formation and clearance in man.
Davies KA; Hird V; Stewart S; Sivolapenko GB; Jose P; Epenetos AA; Walport MJ
J Immunol; 1990 Jun; 144(12):4613-20. PubMed ID: 2141040
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of complement components in polyethylene glycol precipitated immune complexes from patients with ovarian cancer and patients with rheumatoid arthritis.
Mooney NA; Hay FC; Poulton TA
Clin Exp Immunol; 1983 Jun; 52(3):561-8. PubMed ID: 6603297
[TBL] [Abstract][Full Text] [Related]
12. Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes.
Miletic VD; Hester CG; Frank MM
J Immunol; 1996 Jan; 156(2):749-57. PubMed ID: 8543829
[TBL] [Abstract][Full Text] [Related]
13. Antibody-mediated complement activation on nucleated cells. A quantitative analysis of the individual reaction steps.
Ollert MW; Kadlec JV; David K; Petrella EC; Bredehorst R; Vogel CW
J Immunol; 1994 Sep; 153(5):2213-21. PubMed ID: 8051421
[TBL] [Abstract][Full Text] [Related]
14. Effect of H chain V region on complement activation by immobilized immune complexes.
Horgan C; Brown K; Pincus SH
J Immunol; 1992 Jul; 149(1):127-35. PubMed ID: 1607649
[TBL] [Abstract][Full Text] [Related]
15. Complement activation and impaired capacity to solubilize immune complexes or to prevent their formation in essential mixed cryoglobulinemia.
Corvetta A; Spaeth PJ; Ghirelli PA; Orecchioni F; Buetler R; Montroni M; Nydegger UE
Diagn Immunol; 1983; 1(4):315-23. PubMed ID: 6333960
[TBL] [Abstract][Full Text] [Related]
16. Binding of soluble immune complexes to Raji lymphocytes. Role of receptors for complement components, C1q and C3-C3b.
Gupta RC; McDuffie FC; Tappeiner G; Jordon RE
Immunology; 1978 Apr; 34(4):751-61. PubMed ID: 102587
[TBL] [Abstract][Full Text] [Related]
17. Studies on the haemolytic activity of circulating C1q-C3/C4 complexes.
Wouters D; Brouwer MC; Daha MR; Hack CE
Mol Immunol; 2008 Apr; 45(7):1893-9. PubMed ID: 18054386
[TBL] [Abstract][Full Text] [Related]
18. The interaction of human plasma fibronectin with a subunit of the first component of complement, C1q.
Pearlstein E; Sorvillo J; Gigli I
J Immunol; 1982 May; 128(5):2036-9. PubMed ID: 6801128
[TBL] [Abstract][Full Text] [Related]
19. Control of C1 activation by nascent C3b and C4b: a mechanism of feedback inhibition.
Ziccardi RJ
J Immunol; 1986 May; 136(9):3378-83. PubMed ID: 3485688
[TBL] [Abstract][Full Text] [Related]
20. Activation of rat complement by soluble and insoluble rat IgA immune complexes.
Rits M; Hiemstra PS; Bazin H; Van Es LA; Vaerman JP; Daha MR
Eur J Immunol; 1988 Dec; 18(12):1873-80. PubMed ID: 3220102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
